Malecare is pleased to announce several new enhancements to our Advanced Prostate Cancer Program as well as the release of our new Advanced Prostate Cancer Kit which includes our newest publication: RECURRENT PROSTATE CANCER A Working Document for Men with Recurrent Prostate Cancer For many years, Malecare has been the leader in the fight against [...]
Researchers at University of California at San Francisco (UCSF) and GE Healthcare have developed a new technology that appears to rapidly assess the presence and aggressiveness of prostate tumors in real time, by imaging the tumor’s metabolism. […]
This has been an interesting year as men with advanced prostate cancer have seen three different drugs approved. Considering that the prior six years did not have any new drug approvals, this has been a stellar year. First we had Provenge approved, then came Jevtana and now we have added to the list Xgeya (denosumb). [...]
In order to get FDA approval, drugs must first go through a clinical trial that demonstrates that they offer a better treatment result than the current standard of care. In some instances the better result can be a demonstration that the investigational drug provides an advantage which is only palliative (as Mitoxantrone does for advance [...]
The Centers for Medicare & Medicaid Services (CMS) has just issued new rules for Medicare- and Medicaid-participating hospitals that protect patients’ right to choose their own visitors during a hospital stay, including a visitor who is a same-sex domestic partner. […]